QVQuan Duy Vo

Quan Duy Vo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Quan Duy Vo has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The use of artificial intelligence in patent ductus arteriosus diagnosis and treatment: a systematic scoping review

    by Chu Thi Ha, Thi Hai Yen Tran, Minh Nguyet Pham, Phuong Linh Dang, Duy Quan Vo

    Background. Background and objectives: Patent ductus arteriosus (PDA) is a common congenital cardiac condition, especially in premature infants, and is associated with significant morbidity and mortality. Artificial intelligence (AI) has emerged as a promising tool to aid clinicians in diagnosing PDA and guiding treatment decisions amidst this uncertainty. Methods. A literature search (up to December 2025) was conducted in PubMed, Scopus, and Web of Science for peer-reviewed studies on AI (including machine learning, deep learning, computer vision, and predictive analytics) applied to PDA. Results. Seventeen studies were included, predominantly involving preterm neonates. AI applications mainly targeted PDA diagnosis and outcome prediction using clinical and echocardiographic data. Imaging-based deep learning models generally outperformed tabular data approaches (with area under the curve often >0.80). Overall study quality was moderate, with limited external validation and data transparency. Conclusions. AI has the potential to transform patent ductus arteriosus management by enabling earlier detection, more consistent decision-making, and individualized treatment planning. Integration of AI into PDA care may reduce practice variability, improve clinical outcomes, and serve as a model for the broader application of artificial intelligence in medicine.

  • Open Access

    Early diagnosis of gestational diabetes mellitus evidence from Asia countries: A meta‐analysis and systematic review

    by Ke Thi Lan Anh, Nguyen Ngoc Anh, Pham Minh Nguyet, Dang Phuong Linh, Tran Thi Hai Yen, Vo Duy Quan

    Introduction: Gestational diabetes mellitus (GDM) is a common metabolic complication of pregnancy associated with substantial maternal and neonatal morbidity. Asian populations demonstrate increased susceptibility to glucose intolerance and may develop gestational diabetes earlier in pregnancy. However, the prevalence and outcomes of early‐diagnosed gestational diabetes mellitus (E‐GDM) in Asian populations remain incompletely understood. Methods: A systematic review and meta‐analysis was conducted following PRISMA guidelines. PubMed, ScienceDirect, and Web of Science were searched from database inception to February 2026 to identify studies evaluating gestational diabetes diagnosed before 24 weeks of gestation in Asian populations. Results: A total of 2329 records were identified, and 17 studies were included, with 16 eligible studies for meta‐analysis. E‐GDM prevalence ranged from 0.75% to 22.81%, accounting for 9.43%–78.78% of total GDM cases. Compared with conventional GDM, E‐GDM was associated with increased risks of C‐section or instrumental delivery (OR = 1.13, 95% CI 1.01–1.26), preterm birth (OR = 1.38, 95% CI 1.07–1.78), and insulin therapy requirement (OR = 1.60, 95% CI 1.09–2.36). Most neonatal outcomes were similar between groups. Women with E‐GDM showed greater metabolic vulnerability and possible postpartum metabolic dysfunction. Conclusions: E‐GDM in Asian populations identifies women with greater metabolic vulnerability and increased obstetric risk. E‐GDM was associated with higher insulin requirements, increased risks of preterm birth and operative delivery, and possible long‐term metabolic dysfunction. Harmonized diagnostic criteria and region‐specific screening strategies are needed.

  • Open Access

    Evaluating iPSC-based interventions for diabetes: a systematic review and meta-analysis

    by Vu Manh Tan, Ke Thi Lan Anh, Le Thi Dieu Hien, Vu Thi Thu Trang, Pham Minh Nguyet, Dang Phuong Linh, Tran Thi Hai Yen, Vo Duy Quan

    Diabetes mellitus (DM) is characterized by progressive β-cell dysfunction, and current therapies improve glycemic control without restoring endogenous


  • Open Access

    Applications of artificial intelligence in fetal MRI: a systematic review

    by Yen Vu Thi Hai, Duy Le Cao Phuong, Quan Vo Duy

    Background: Magnetic resonance imaging (MRI) plays a pivotal role in obstetric care, offering high-resolution visualization for assessing fetal abnormalities, especially when ultrasound has limitations. Despite its advantages, MRI faces challenges such as motion artifacts and extended imaging durations, which can hinder diagnostic accuracy. The integration of artificial intelligence (AI) has demonstrated significant potential in overcoming these challenges by enhancing image quality, enabling precise segmentation, and automating diagnostic workflows. Continued evaluation and rigorous validation are essential to optimize AI’s clinical utility, ensuring its safe and effective application in prenatal care. Methods: In November 2024, data were collected from three electronic databases—PubMed, Web of Science, and ScienceDirect—to explore AI applications in fetal MRI. Result: Out of 1587 articles, 95 studies were included in this review. Key focuses include segmentation (37%), motion correction (22%), and disease prediction (18%). The fetal brain was the main anatomical target (53.6%). AI models like convolutional neural networks (CNNs) and U-Nets excel in segmentation and enhancement, with accuracy often over 90%. However, only 29.9% of studies provided data or code, and 69.8% included interpretability tools, highlighting reproducibility and clinical applicability challenges. Conclusion: AI is transforming fetal MRI by improving segmentation, motion correction, and anomaly detection, especially through CNN models. Increased transparency, data access, and interpretability are crucial for clinical trust and integration into prenatal care, enhancing diagnostic precision and patient care.


  • Biomaterial platforms in cardiovascular regenerative medicine – challenges and future perspectives

    by Quan Duy Vo

    Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, responsible for about 17.9 million deaths annually. Induced pluripotent stem cells (iPSCs) offer a patient-specific and ethically acceptable source for cardiac regeneration. Early applications using two-dimensional cultures or direct cell injection showed feasibility but were limited by poor retention and immaturity. Biomaterial-based approaches now provide supportive environments that enhance cell survival, alignment, and integration. iPSC - biomaterial platforms combining scaffolds, hydrogels, and engineered matrices have improved tissue organization and functional performance. However, persistent challenges such as incomplete maturation, arrhythmogenic risk, high production costs, and regulatory hurdles remain. Future progress will depend on integrating advanced biomaterials, gene editing, artificial intelligence, and scalable GMP-compliant manufacturing. By bridging stem cell biology and materials science, iPSC - biomaterial systems represent a promising path toward clinically viable cardiac regeneration.


  • Open Access

    Pulmonary glue embolism and interstitial pneumonitis following endoscopic cyanoacrylate injection: A case report

    by Duy Le Cao Phuong, Thi Tran Van, Huy Tran Thanh, Uyen Tran Ha, Tien Nguyen Vo Anh, Thong Duong Minh, Quan Vo Duy

    Endoscopic injection of a cyanoacrylate-lipiodol mixture is widely regarded as the first-line treatment for gastrointestinal bleeding secondary to ruptured gastric varices. Although generally effective, this technique carries the risk of rare but potentially life-threatening complications, including pulmonary glue embolism and interstitial pneumonitis. We present the case of a 65-year-old woman with cirrhosis who presented with hematemesis and melena and underwent endoscopic cyanoacrylate-lipiodol injection for bleeding gastroesophageal varices. Within 24 hours, she developed a persistent fever and bilateral crackles. Chest X-ray, CT imaging, and bronchoscopy findings were consistent with glue-induced pneumonitis. Corticosteroid therapy resulted in rapid clinical and radiological improvement. This case highlights the importance of recognising pulmonary complications following cyanoacrylate injection for gastric varices and underscores the need for prompt diagnosis and appropriate management to mitigate morbidity.


  • Open Access

    Outcomes of percutaneous coronary intervention in COVID-19-positive acute coronary syndrome patients: a retrospective study in Vietnam

    by Duy Cao Phuong Le, Nguyet Thi Minh Nguyen, Quan Duy Vo

    Background: Coronavirus disease 2019 (COVID-19) has disrupted the management of acute coronary syndrome (ACS), with emerging evidence suggesting increased complications and mortality among patients undergoing percutaneous coronary intervention (PCI). However, data from low- and middle-income settings such as Vietnam remain limited. This study aimed to evaluate the clinical characteristics and outcomes of ACS patients with COVID-19 undergoing PCI at a tertiary hospital in Vietnam.Methods: This retrospective cohort study was conducted at a tertiary hospital in Ho Chi Minh City from 2019 to 2022. Adult patients diagnosed with ACS who underwent PCI were included and stratified by COVID-19 status confirmed via RT-PCR. All patients received standard guideline-directed therapy, including dual antiplatelet and anticoagulant regimens, and were followed for 1 year to assess clinical outcomes.Result: A total of 118 patients were included, comprising 26 COVID-19-positive and 92 COVID-19-negative individuals. Baseline characteristics and cardiovascular risk factors were generally comparable between the two groups. While procedural success rates were similar, COVID-19-positive patients demonstrated higher thrombus burden and significantly increased rates of ICU admission, prolonged hospitalization, and MACCE at all timepoints. COVID-19 severity, cardiogenic shock, and multivessel disease emerged as independent predictors of adverse outcomes.Conclusion: In this Vietnamese cohort, COVID-19 infection was associated with worse clinical outcomes following PCI for ACS. These findings highlight the need for early risk stratification and resource planning during pandemic conditions. However, the small sample size, single-center design, and observational nature of the study limit its generalizability, and causal inferences should be drawn with caution.


  • Open Access

    Gene editing therapy as a therapeutic approach for cardiovascular diseases in animal models: A scoping review

    by Quan Duy Vo

    Background: Cardiovascular diseases (CVDs) are the leading cause of mortality worldwide, with hereditary genetic factors contributing substantially to disease burden. Current treatments, including lifestyle modifications, pharmacotherapy, and surgical interventions, focus primarily on symptom management but fail to address underlying genetic causes, often resulting in disease progression or recurrence. Gene therapy has emerged as a transformative approach, offering a potential treatment. This review explores its efficacy and safety in animal models, identifying opportunities for future advancements. Methods: This review investigated studies on gene editing interventions in animal models of CVDs, retrieved from PubMed, ScienceDirect, and Web of Science up to December 2024. Result: A total of 57 studies were included in this review. Mice (86%) were the predominant model, with CRISPR-Cas9 (53%) and AAV vectors (80%) as the most used tools. Key targets included PCSK9 (32%), LDLR (9%), and MYH6/7 (7%), achieving 25–85% editing efficiency in liver/heart tissues. Base editors (ABE/CBE) showed superior safety, with <1% off-targets versus CRISPR-Cas9’s 2–5 off-targets per guide. Reported toxicity risks included liver injury (AAVs, 23%) and transient cytokine elevation (LNPs, 14%). Conclusion: Gene editing therapy shows great potential for treating CVDs, with high efficiency, strong therapeutic outcomes, and favorable safety in animal models. Continued innovation and rigorous evaluation could transform cardiovascular treatment, benefiting patients with untreatable conditions.


  • Open Access

    Percutaneous coronary intervention using iso-osmolar contrast agent in an end-stage renal failure patient: a case report

    by Duy Cao Phu’o’nG Le, Hoa The Bui, Quan Duy Vo

    Background: Managing acute myocardial infarction (AMI) in end-stage renal failure (ESRF) patients poses challenges, particularly the risk of contrast-induced nephropathy (CIN) during percutaneous coronary intervention (PCI). This case highlights the successful use of iodixanol, an iso-osmolar contrast agent, in an ESRF patient who declined dialysis with no renal function deterioration. It underscores the potential of iodixanol in safely managing high-risk patients, offering insights for clinical practice. Case presentation: A 79-year-old male with non-ST-elevation myocardial infarction (NSTEMI) and end-stage renal failure (ESRF), who had declined dialysis, underwent PCI using iodixanol. Coronary angiography revealed significant left main and triple vessel disease, and coronary artery bypass grafting (CABG) was declined by the patient. A second intervention was performed one week later due to persistent symptoms. Post-procedural monitoring revealed stage 1 acute kidney injury (AKI), which was successfully managed with intravenous fluid therapy. Renal function stabilized after the second procedure, and the patient was discharged one week later. Conclusion: The use of iodixanol in ESRF patients undergoing PCI without dialysis appears to be a favorable option. Further studies are needed to guide contrast agent selection in this high-risk group.

  • Open Access

    Induced Pluripotent Stem Cells in Cardiomyopathy: Advancing Disease Modeling, Therapeutic Development, and Regenerative Therapy

    by Quan Duy Vo, Kazufumi Nakamura, Yukihiro Saito, Satoshi Akagi, Toru Miyoshi, Shinsuke Yuasa

    Cardiomyopathies are a heterogeneous group of heart muscle diseases that can lead to heart failure, arrhythmias, and sudden cardiac death. Traditional animal models and in vitro systems have limitations in replicating the complex pathology of human cardiomyopathies. Induced pluripotent stem cells (iPSCs) offer a transformative platform by enabling the generation of patient-specific cardiomyocytes, thus opening new avenues for disease modeling, drug discovery, and regenerative therapy. This process involves reprogramming somatic cells into iPSCs and subsequently differentiating them into functional cardiomyocytes, which can be characterized using techniques such as electrophysiology, contractility assays, and gene expression profiling. iPSC-derived cardiomyocyte (iPSC-CM) platforms are also being explored for drug screening and personalized medicine, including high-throughput testing for cardiotoxicity and the identification of patient-tailored therapies. While iPSC-CMs already serve as valuable models for understanding disease mechanisms and screening drugs, ongoing advances in maturation and bioengineering are bringing iPSC-based therapies closer to clinical application. Furthermore, the integration of multi-omics approaches and artificial intelligence (AI) is enhancing the predictive power of iPSC models. iPSC-based technologies are paving the way for a new era of personalized cardiology, with the potential to revolutionize the management of cardiomyopathies through patient-specific insights and regenerative strategies.